45 results about "Conventional chemotherapy" patented technology

A method, and system, to induce remission in diseases characterized by excess production of sTNR and interleukin 2 has been developed. In the most preferred embodiment, the system consists of antibodies to sTNFR1, sTNFR2 and sIL2R immobilized in a column containing a material such as SEPHAROSE™. The patient is connected to a pheresis machine which separates the blood into the plasma and red cells, and the plasma is circulated through the column until the desired reduction in levels of sTNFR1, sTNFR2, and IL2 is achieved, preferably to less than normal levels. In the preferred method, patients are treated three times a week for four weeks. This process can be repeated after a period of time. Clinical studies showed reduction in tumor burden in patients having failed conventional chemotherapy and radiation treatments.

A method, and system, to induce remission in diseases characterized by excess production of sTNR and interleukin 2 has been developed. In the most preferred embodiment, the system consists of antibodies to sTNFR1, sTNFR2 and sIL2R immobilized in a column containing a material such as SEPHAROSE™. The patient is connected to a pheresis machine which separates the blood into the plasma and red cells, and the plasma is circulated through the column until the desired reduction in levels of sTNFR1, sTNFR2, and IL2 is achieved, preferably to less than normal levels. In the preferred method, patients are treated three times a week for four weeks. This process can be repeated after a period of time. Clinical studies showed reduction in tumor burden in patients having failed conventional chemotherapy and radiation treatments.

The invention provides methods for predicting whether an ovarian cancer patient's tumor will be resistant to chemotherapy. The invention also provides methods for monitoring the effectiveness of treatment, particularly a chemotherapeutic treatment, in a patient treated for ovarian cancer. The invention further provides methods for treating ovarian cancer, by reducing chemotherapeutic drug resistance in said cells. In addition, the invention provides methods of screening compounds to identify tumor cell growth inhibitors in tumor cells resistant to conventional chemotherapeutic treatment regimes.

The invention provides a method for separating leukemia stem cells from a leukemia cell strain, which comprises the following steps: firstly, subculturing human acute myelogenous leukemia cell strain KD1a cells; and secondly, separating CD34+CD38-cells by an immunomagnetic bead separation method to obtain the leukemia stem cells, wherein the leukemia stem cells can resist conventional chemotherapy and NK immunization therapy. The separation method disclosed by the invention is simple to operate, can separate a large quantity of high-purity leukemia stem cells from KG1a cells, and has an important significance for the research of the leukemia stem cells.

The invention provides an Erianin nano preparation and a preparation method and application thereof. The Erianin nano preparation comprises the following raw materials by weight: 15 to 25 parts of Erianin monomers, 20 to 30 parts of a W / O type emulsifier, 70 to 80 parts of lecithin, 10 to 20 parts of ethanol, and 45 to 55 parts of an O / W type emulsifier. The Erianin nano preparation of the invention breaks through the bottleneck of poor water solubility of the Erianin and cannot be applied clinically, focuses on preparing the poorly soluble monomeric Erianin into related nano preparations, andpushes the Erianin to a clinical application stage. The Erianin nano preparation can solve the defects of poor targetability and many adverse reactions of conventional chemotherapeutic drugs. The nano preparation prepared by the invention has good targeting to the liver of mice, and is expected to be a related targeted preparation for treating primary liver cancer.

Disclosed is a novel vaccine against Escherichia coli (E. coli) responsible for urinary tract infections. The vaccine is a recombinant chimeric protein which is prepared by linking by genetic recombination a gene encoding an antigenic determinant of uropathogenic E. coli to a CTXA2B gene encoding nontoxic A2 and B subunits of Vibrio cholerae cholera toxin (CTX) or a LTXA2B gene encoding nontoxic A2 and B subunits of E. coli heat-labile enterotoxin, wherein a translation product of the CTXA2B or LTXA2B gene serves as an immunogenic adjuvant stimulating mucosal immune responses, expressing the resulting recombinant gene in E. coli, and isolating and purifying an expressed recombinant fusion protein. The recombinant chimeric protein is useful as an oral vaccine with mild side effects and excellent vaccination efficiency against uropathogenic E. coli. Thus, the chimeric vaccine protein can remarkably reduce recurrence of urinary tract infections, prevent occurrence of antibiotic-resistant bacteria, and replace the conventional chemotherapy for urinary tract infections. Also, the chimeric vaccine protein has other advantages of being capable of being produced and commercialized in a short period with relatively low costs, and being easily modified by replacing its genetic constituents with other genes to provide various vaccines.

The invention relates to a combination of compounds derived from gallic acid, with an antitumoral and antimetastatic activity via a mechanism that involves the induction of apoptosis and the immunogenic death of the tumor cells and the subsequent activation of the specific immune response. The invention also relates to a composition containing a combination of derivatives of gallic acid and pharmaceutically acceptable excipients for the production of useful medicaments in the treatment of cancer. The invention further relates to the use of said composition in a coadjuvant in conventional chemotherapy, reducing the doses of chemotherapeutic agents used in the treatment of cancer.

The invention relates to methods for predicting the clinical outcome of cancer patients, and in particular of acute lymphoblastic leukaemia (ALL) patients, in response to a therapy against ALL, preferably conventional chemotherapy, more preferably based on glucocorticoids, said methods based on the presence of particular polymorphism in genes coding for drug-metabolizing enzymes and apoptotic proteins. The invention relates as well to method for predicting the efficacy of a therapy based on conventional glucocorticoids as well as to method for personalized medicine in patients carrying said polymorphisms.

The present invention relates to a repurposed antibiotic compound for the treatment of cancer with minimal nuclear gene damage and an anticancer pharmaceutical composition comprising same. Since the repurposed antibiotic compound has a therapeutic effect in a manner that targets only the mitochondria of cancer cells, the modified antibiotic compound does not cause gene degeneration unlike conventional chemotherapy which damages nuclear DNAs to kill cancer cells,, thereby preventing the recurrence of cancer. In addition, a mitochondria targeted therapy using the compound according to the present invention can effectively treat malignant tumors that are difficult to treat due to acquiring drug resistance by general anticancer treatment.

The invention discloses tetrahydropyridinopyran-monoclonal antibody CD14 conjugates with anti-tumor activity and a preparation method and use thereof. The structure of the conjugate is represented by a formula (II). Under the action of dicyclohexylcarbodiimide (DCC) serving as a condensing agent, an amino acid residue on the carbon terminal of a CD14 monoclonal molecule is bonded with an amino on a pyran ring in a tetrahydropyridinopyran derivative to form a monoclonal antibody conjugate CD14-TPP of the formula (II). CD14-TPP can effectively inhibit the proliferation of a human erythroleukemia cell line K562, an ovarian cancer cell line MDR-MB-231 and a liver cancer cell line SMMC-7721 with an IC50 value much lower than 5-fluorouracil (5Fu) which is a conventional chemotherapy medicine. The conjugate of the formula (II) with low toxic effect on normal bone narrow cells of mouse can be used for preparing medicines for treating leukemia, ovarian cancer and liver cancer.

The invention relates to the application of marine biological metabolite Tagalsin C and its homologues Tagalsins A, B, D, E, F, G in the preparation of antitumor drugs. This series of compounds has membrane permeability and broad-spectrum anti-tumor activity, and can kill human promyelocytic acute leukemia cells HL-60, human myeloma cells IM9, human acute T-cell leukemia cells Jurkat, and human macrophage lymphoma cells U937, human lung cancer cell A549, human breast cancer cell MCF-7 and MDA-MB-231, human liver cancer cell HepG2, human prostate cancer cell PC-3 and human cervical cancer epithelial cell Hela, while normal cell human kidney blast 293 And the human liver diploid cell L02 has no obvious killing ability, and can be applied to the preparation of drugs for treating tumors, drugs for treating clinical high expression of Bcl-2, resistant to conventional chemotherapy, and drugs for treating recurrent cancer.

The invention relates to a curcumin compound preparation for treating cancer. By using curcumin, pterostilbene and δ-tocotrienol as raw materials and carrying out a suitable weight ratio, the three components are synergistically The number of anti-cancer targets and the anti-cancer spectrum are superimposed, and the anti-cancer effect is significantly multiplied. The curcumin in the curcumin compound preparation of the present invention can kill cancer stem cells, and can significantly reduce the recurrence rate of cancer compared with conventional chemotherapy methods that cannot kill cancer stem cells. The invention is non-toxic to human body and will not produce adverse reactions when applied in large doses. And the treatment cost is expected to be less than half or lower than that of conventional chemotherapy drugs, and far lower than the high treatment cost of cellular immunotherapy CAR‑T, which has broad application prospects in the field of cancer treatment.